E. K. Donyush
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
E. K. Donyush has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- E. A. Pristanskova
Russian Children's Clinical Hospital of the N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation
3 shared publications - Elena V. Skorobogatova
N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation
3 shared publications - Kirill I. Kirgizov
Research Institute of Pediatric Oncology and Hematology, FSBI “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of Russia, Kashirskoye sh. 23, Moscow 115522, Russia
3 shared publications - Roman V. Garbuzov
Russian Children's Clinical Hospital of Pirogov Russian National Research Medical University
3 shared publications - Yuri Alexandrovich Polyaev
Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
3 shared publications - Z. A. Kondrashova
Russian Children's Clinical Hospital of Pirogov Russian National Research Medical University; Pirogov Russian National Research Medical University
3 shared publications
Latest Publications
- 24 October 2023
- Published by ECO-Vector LLC in Russian Journal of Pediatric Surgery
- Vol. 27 (4) , 261-271
Kaposiform hemangioendotheliomas and tufted angiomas: Sirolimus for treating children
Introduction. Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are extremely rare vascular tumors characterized by pathologically progressive angiogenesis and lymphangiogenesis. They are also associated with the development of the KazabachMerritt Phenomenon (KMP; Kasabach-Merritt Phenomenon).Material and methods. 8 patients (5 boys, 3 girls) with kaposiform hemangioendothelioma (two out of them with Kazabakh-Merritt syndrome) and 4 patients (3 boys, 1 girl) with tufted angioma were treated at the Russian Children's Clinical Hospital of Pirogov Russian National Research Medical University (Moscow, Russia) . All patients were prescribed Sirolimus therapy for antiproliferative purpose.Results. In all children, positive changes were registered: reduction of vascular tumor volume, gradual improvement of clinical picture and control of complications: pain syndrome, KMP, improvement or restoration of functions in affected organs /systems (increase/restoration of movement volume in joints, compensation for length discrepancy in lower legs). Complete resorption of vascular tumors and clinical symptoms were registered in 3 patients.Conclusion. The obtained encouraging results after Sirolimus therapy prescribed for treating KME and TA allow the authors to recommend this therapy to patients with KME with or without KMP and TA. However, further researches with a large sample of participants is required to confirm the obtained results.
- 24 October 2023
- Published by ECO-Vector LLC in Russian Journal of Pediatric Surgery
- Vol. 27 (4) , 261-271
Kaposiform hemangioendotheliomas and tufted angiomas: Sirolimus for treating children
Introduction. Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are extremely rare vascular tumors characterized by pathologically progressive angiogenesis and lymphangiogenesis. They are also associated with the development of the KazabachMerritt Phenomenon (KMP; Kasabach-Merritt Phenomenon).Material and methods. 8 patients (5 boys, 3 girls) with kaposiform hemangioendothelioma (two out of them with Kazabakh-Merritt syndrome) and 4 patients (3 boys, 1 girl) with tufted angioma were treated at the Russian Children's Clinical Hospital of Pirogov Russian National Research Medical University (Moscow, Russia) . All patients were prescribed Sirolimus therapy for antiproliferative purpose.Results. In all children, positive changes were registered: reduction of vascular tumor volume, gradual improvement of clinical picture and control of complications: pain syndrome, KMP, improvement or restoration of functions in affected organs /systems (increase/restoration of movement volume in joints, compensation for length discrepancy in lower legs). Complete resorption of vascular tumors and clinical symptoms were registered in 3 patients.Conclusion. The obtained encouraging results after Sirolimus therapy prescribed for treating KME and TA allow the authors to recommend this therapy to patients with KME with or without KMP and TA. However, further researches with a large sample of participants is required to confirm the obtained results.
- Open Access
- 19 July 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (2) , 117-130
Consensus on the diagnosis and treatment of PROS (PIK3CA-related overgrowth spectrum). Russian version
PROS (PIK3CA-Related Overgrowth Spectrum) encompasses vascular malformations, lipomatosis and other multiple congenital anomalies resulting from activating somatic mutations in the PIK3CA gene. PROS includes macrodactyly, hemimegalencephaly, muscle hemihypertrophy, facial infiltrating lipomatosis CLOVES, megalencephaly, vascular malformations (capillary, venous, lymphatic, arteriovenous and combined vascular malformations), skin disorders, epidermal nevi, etc.The experts of the Russian Society of Pediatric Oncologists and Hematologists, Russian Association of Pediatric Surgeons and Russian Society of Medical Geneticists developed this consensus statement of diagnostics and treatment of PROS.
- 19 July 2023
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 10 (2) , 117-130
Open AccessConsensus on the diagnosis and treatment of PROS (PIK3CA-related overgrowth spectrum). Russian version
PROS (PIK3CA-Related Overgrowth Spectrum) encompasses vascular malformations, lipomatosis and other multiple congenital anomalies resulting from activating somatic mutations in the PIK3CA gene. PROS includes macrodactyly, hemimegalencephaly, muscle hemihypertrophy, facial infiltrating lipomatosis CLOVES, megalencephaly, vascular malformations (capillary, venous, lymphatic, arteriovenous and combined vascular malformations), skin disorders, epidermal nevi, etc.The experts of the Russian Society of Pediatric Oncologists and Hematologists, Russian Association of Pediatric Surgeons and Russian Society of Medical Geneticists developed this consensus statement of diagnostics and treatment of PROS.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 87 (5) , 92-98
Unilateral subjective tinnitus «vanishing bone» disease (Goram—Stout syndrome).
Представлена история болезни девочки 11 лет с болезнью Горхема—Стоута, дебютировавшей с одностороннего субъективного ушного шума. Выполнен обзор описанных в литературе клинических случаев с поражением височных костей и современных способов лечения данного заболевания.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 87 (5) , 92-98
Unilateral subjective tinnitus «vanishing bone» disease (Goram—Stout syndrome).
Представлена история болезни девочки 11 лет с болезнью Горхема—Стоута, дебютировавшей с одностороннего субъективного ушного шума. Выполнен обзор описанных в литературе клинических случаев с поражением височных костей и современных способов лечения данного заболевания.
- Open Access
- 22 December 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (4) , 65-76
MECOM-associated syndrome: a literature review and case reports
Mutations in the MECOM gene (MDS1 and EVI1 complex locus) may be one of the causes of a rare combination of congenital radioulnar synostosis resulting in extremely limited forearm pronation and supination, and amegakaryocytic thrombocytopenia. The clinical spectrum of the disease can range from isolated radioulnar synostosis with or without hematologic manifestations to severe bone marrow failure without skeletal abnormalities. Other phenotypic manifestations include clinodactyly, brachydactyly, cardiac and renal malformations, presenile hearing loss, and B-cell deficiency. In view of the heterogeneity of phenotypic manifestations of the disease, the term “MECOM-associated syndrome” was proposed for all patients with mutations in the MECOM gene. Here we report 3 pediatric cases of MECOM-associated syndrome with different clinical manifestations, diagnostic approaches, therapeutic options, and outcomes. The patient’s parents agreed to use the information, including the child’s photo, in scientific research and publications.
- 22 December 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (4) , 65-76
Open AccessMECOM-associated syndrome: a literature review and case reports
Mutations in the MECOM gene (MDS1 and EVI1 complex locus) may be one of the causes of a rare combination of congenital radioulnar synostosis resulting in extremely limited forearm pronation and supination, and amegakaryocytic thrombocytopenia. The clinical spectrum of the disease can range from isolated radioulnar synostosis with or without hematologic manifestations to severe bone marrow failure without skeletal abnormalities. Other phenotypic manifestations include clinodactyly, brachydactyly, cardiac and renal malformations, presenile hearing loss, and B-cell deficiency. In view of the heterogeneity of phenotypic manifestations of the disease, the term “MECOM-associated syndrome” was proposed for all patients with mutations in the MECOM gene. Here we report 3 pediatric cases of MECOM-associated syndrome with different clinical manifestations, diagnostic approaches, therapeutic options, and outcomes. The patient’s parents agreed to use the information, including the child’s photo, in scientific research and publications.
- 12 April 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (2)
PRACTICAL ASPECTS OF THE APPLICATION OF INTRAVENOUS IMMUNOGLOBULINS FOR INTRAVENOUS ADMINISTRATION IN VARIOUS PATHOLOGIES
Human intravenous immunoglobulin (IVIG) – a blood product prepared from the serum of many healthy donors, is the mainstay of therapy for treatment of primary immunodeficiencies, is increasingly used in various fields of medicine. The article reflects practical aspects of use of this group of drugs in a multidisciplinary pediatric hospital not only taking the therapy of defects of the immune system as an example, but also oncohematological, neurological, dermatological diseases, including orphan diseases. The modern data on the mechanisms of action of immunoglobulins, schemes of use for various pathologies are presented. The issues of safety of application, interchangeability of immunoglobulins from different manufacturers are considered.
- 12 April 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (2)
PRACTICAL ASPECTS OF THE APPLICATION OF INTRAVENOUS IMMUNOGLOBULINS FOR INTRAVENOUS ADMINISTRATION IN VARIOUS PATHOLOGIES
Human intravenous immunoglobulin (IVIG) – a blood product prepared from the serum of many healthy donors, is the mainstay of therapy for treatment of primary immunodeficiencies, is increasingly used in various fields of medicine. The article reflects practical aspects of use of this group of drugs in a multidisciplinary pediatric hospital not only taking the therapy of defects of the immune system as an example, but also oncohematological, neurological, dermatological diseases, including orphan diseases. The modern data on the mechanisms of action of immunoglobulins, schemes of use for various pathologies are presented. The issues of safety of application, interchangeability of immunoglobulins from different manufacturers are considered.
- Open Access
- 21 September 2020
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 7 (3) , 22-31
Sirolimus for the treatment of vascular anomalies in children
Vascular anomalies (VA) comprise a heterogeneous group of diseases associated with congenital angiogenesis disorder. There are no currently developed unified protocols and treatment regimens for systemic forms of VA. Numerous advantages show sirolimus, an mTOR inhibitor, as a well tolerated and effective antiproliferative and antiangiogenic therapy in patients with VA. The article presents the results of treatment of 211 patients with VA (6 patients with vascular tumors and 205 patients with vascular malformations) aged 2 months to 17 years (median – 9 years), who received sirolimus therapy for 1–86 months (median – 24 months). Sirolimus was administered at a starting dose of 0.8 mg/m2/day orally in two doses with an interval of 12 hours. The concentration of the blood preparation was maintained in the therapeutic range of 6–15 ng/ml. Since 2015, concomitant therapy with co-trimoxazole for the prevention of Pneumocystis pneumonia has been prescribed only to tracheostomy carriers. When infectious episodes occurred in patients, sirolimus therapy continued without changes in the dose of the drug and did not affect the disease, provided that the therapeutic concentration was maintained. A positive response to therapy was observed in 89.1 % of patients with VA in the form of the size of the vascular mass according to the data of visual examination and instrumental control. All patients showeda clinical response to therapy in the form of relief of painsyndrome, reduction/relief of lymphorrhea, reduction/improvement of hemostasis parameters, and an increase in functional activity and quality. For the entire observation period 2012–2020, when taking sirolimus, not a single severe adverse event occurring in post-transplant patients has been reported that would require discontinuation of the drug. The article presents two clinical cases of sirolimus use in the treatment of patients with kaposiform hemangioendothelioma and extensive venous malformation. Parents are encouraged to use the information in scientific research and publications.
- 21 September 2020
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 7 (3) , 22-31
Open AccessSirolimus for the treatment of vascular anomalies in children
Vascular anomalies (VA) comprise a heterogeneous group of diseases associated with congenital angiogenesis disorder. There are no currently developed unified protocols and treatment regimens for systemic forms of VA. Numerous advantages show sirolimus, an mTOR inhibitor, as a well tolerated and effective antiproliferative and antiangiogenic therapy in patients with VA. The article presents the results of treatment of 211 patients with VA (6 patients with vascular tumors and 205 patients with vascular malformations) aged 2 months to 17 years (median – 9 years), who received sirolimus therapy for 1–86 months (median – 24 months). Sirolimus was administered at a starting dose of 0.8 mg/m2/day orally in two doses with an interval of 12 hours. The concentration of the blood preparation was maintained in the therapeutic range of 6–15 ng/ml. Since 2015, concomitant therapy with co-trimoxazole for the prevention of Pneumocystis pneumonia has been prescribed only to tracheostomy carriers. When infectious episodes occurred in patients, sirolimus therapy continued without changes in the dose of the drug and did not affect the disease, provided that the therapeutic concentration was maintained. A positive response to therapy was observed in 89.1 % of patients with VA in the form of the size of the vascular mass according to the data of visual examination and instrumental control. All patients showeda clinical response to therapy in the form of relief of painsyndrome, reduction/relief of lymphorrhea, reduction/improvement of hemostasis parameters, and an increase in functional activity and quality. For the entire observation period 2012–2020, when taking sirolimus, not a single severe adverse event occurring in post-transplant patients has been reported that would require discontinuation of the drug. The article presents two clinical cases of sirolimus use in the treatment of patients with kaposiform hemangioendothelioma and extensive venous malformation. Parents are encouraged to use the information in scientific research and publications.
- 10 December 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (6)
HURLER SYNDROME: 15 YEARS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH HURLER SYNDROME AT THE RUSSIAN CHILDREN’S CLINICAL HOSPITAL
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- 10 December 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (6)
HURLER SYNDROME: 15 YEARS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH HURLER SYNDROME AT THE RUSSIAN CHILDREN’S CLINICAL HOSPITAL
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- 10 December 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (6)
GASTROINTESTINAL MOTILITY IN CHILDREN WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- 10 December 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (6)
GASTROINTESTINAL MOTILITY IN CHILDREN WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- Open Access
- 12 January 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (4)
Mucopolysaccharidosis I type: new management
Mucopolysaccharidosis I-Hurler (MPS I-H) is the most severe form of a metabolic genetic disease caused by mutations of IDUA gene encoding the lysosomal α-L-iduronidase enzyme. MPS I-H is a rare, life-threatening disease, evolving in multisystem morbidity including progressive neurological disease, upper airway obstruction, skeletal deformity and cardiomyopathy. Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the gold standard for the treatment of MPS I-H in patients diagnosed and treated before 2–2.5 years of age, having a high rate of success. Enzyme replacement therapy (ERT) with human recombinant laronidase has also been demonstrated to be effective in ameliorating the clinical conditions of pre-transplant MPS I-H patients and in improving HSCT outcome, by peri-transplant co-administration. Nevertheless the long-term clinical outcome even after successful HSCT varies considerably, with a persisting residual disease burden. This review will focus on all these critical issues related to the management of MPS I-H.
- 12 January 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (4)
Open AccessMucopolysaccharidosis I type: new management
Mucopolysaccharidosis I-Hurler (MPS I-H) is the most severe form of a metabolic genetic disease caused by mutations of IDUA gene encoding the lysosomal α-L-iduronidase enzyme. MPS I-H is a rare, life-threatening disease, evolving in multisystem morbidity including progressive neurological disease, upper airway obstruction, skeletal deformity and cardiomyopathy. Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the gold standard for the treatment of MPS I-H in patients diagnosed and treated before 2–2.5 years of age, having a high rate of success. Enzyme replacement therapy (ERT) with human recombinant laronidase has also been demonstrated to be effective in ameliorating the clinical conditions of pre-transplant MPS I-H patients and in improving HSCT outcome, by peri-transplant co-administration. Nevertheless the long-term clinical outcome even after successful HSCT varies considerably, with a persisting residual disease burden. This review will focus on all these critical issues related to the management of MPS I-H.